Nureca Board Approves Q4 FY26 Results, Appoints New CFO, and Approves Capex
Nureca Limited approved audited financial results for Q4 FY26. The company appointed Mr. Chander Kant as CFO and approved re-appointments of Mr. Aryan Goyal (Whole Time Director & CEO), Mr. Saurabh Goyal (Managing Director), and Ms. Smita Goyal (Additional Director). An incremental capex of up to ₹100 crore was sanctioned for manufacturing expansion.
The appointment of a new CFO, re-appointments of key directors, and a substantial capex approval for manufacturing expansion are material events that can significantly impact the company's future performance and strategic direction.
The company reported its financial results, approved appointments and re-appointments of key personnel, and sanctioned a significant capex for expansion, indicating positive operational and strategic developments.
Nureca Limited announced the outcome of its Board Meeting held on May 29, 2026. The Board approved the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended March 31, 2026, with an unmodified opinion from the Statutory Auditors.
The company also approved the appointment of M/s MGSG and Associates as Internal Auditor for the Financial Year 2026-27. Furthermore, Mr. Chander Kant was appointed as the Chief Financial Officer (CFO) and Key Managerial Personnel (KMP) effective June 27, 2026, following the resignation of Mr. Naresh Gupta from the same position, with his last working day being June 26, 2026.
Key re-appointments were also approved, subject to shareholder approval at the upcoming Annual General Meeting (AGM): Mr. Aryan Goyal as Whole Time Director & CEO for three years from May 28, 2027; Mr. Saurabh Goyal as Managing Director for three years from September 3, 2026; and Ms. Smita Goyal as Additional Director (Whole Time Director) for three years from June 1, 2026. Mr. Aryan Goyal will also retire by rotation at the ensuing 10th AGM.
The Board approved an incremental capex of up to ₹100 crore for plant and machinery to manufacture additional medical devices, healthcare consumables, and hygiene products at their existing industrial land in Sundran, Punjab. Additionally, the company will purchase adjoining land for future expansion.
The 10th AGM is scheduled for Tuesday, July 28, 2026, conducted via video conferencing. The Register of Members and Share Transfer Books will be closed from July 22, 2026, to July 28, 2026, inclusive, for the AGM.
What to do with a filing like this
Nureca Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Nureca Limited. Read the original for the full detail.